Albert Einstein College of Medicine Awarded $1 Million Challenge Gift for COVID-19 Research from the Price Family Foundation
June 2, 2020—(BRONX, NY)—Albert Einstein College of Medicine has received a $1 million challenge grant from Michael F. Price and the Price Family Foundation to support COVID-19 research. The foundation will match donations to Einstein for research on the novel coronavirus, dollar-for-dollar, up to $1 million. (Source: Einstein News)
Source: Einstein News - June 2, 2020 Category: Universities & Medical Training Source Type: news

Montefiore and Einstein Test a New Drug Combination to Conquer COVID-19
May 26, 2020—(BRONX, NY)—Montefiore Health System andAlbert Einstein College of Medicine have begun the next stage of the Adaptive COVID-19 Treatment Trial (ACTT), to evaluate treatment options for people hospitalized with severe COVID-19 infection. The new iteration of the trial, known as ACTT 2, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. (Source: Einstein News)
Source: Einstein News - May 26, 2020 Category: Universities & Medical Training Source Type: news

Einstein Celebrates 62nd Commencement with Historic Virtual Ceremony
May 26, 2020—(BRONX, N.Y)—Later today,Albert Einstein College of Medicine will celebrate the Class of 2020 by holding its first-ever virtual commencement ceremony. The event will honor Einstein’s 202 graduating medical and graduate students and confer them with their well-earned degrees. (Source: Einstein News)
Source: Einstein News - May 26, 2020 Category: Universities & Medical Training Source Type: news

A Promising Drug for the Treatment of Severe Lung Inflammation in COVID-19 Patients: Montefiore-Einstein Scientists Lead Two Trials of Leronlimab
May 21, 2020—BRONX, NY—Montefiore Health System andAlbert Einstein College of Medicine are the first sites in the nation to begin evaluating an investigational drug in two separate, FDA-approved trials: one to treat mild-to-moderate cases of COVID-19 and the other to treat severely ill COVID-19 patients. They are hopeful that the drug, leronlimab, may prevent the“cytokine storm” that inflames and fatally damages the lungs and other organs of many COVID-19 patients. (Source: Einstein News)
Source: Einstein News - May 22, 2020 Category: Universities & Medical Training Source Type: news

Children Not Immune to Coronavirus: New Study from Pandemic Epicenter Describes Severe COVID-19 Response in Children
NEW YORK (May 19, 2020)— While most children infected with the novel coronavirus have mild symptoms, a subset requires hospitalization and a small number require intensive care. A new report from pediatric anesthesiologists, infectious disease specialists and pediatricians at theChildren’s Hospital at Montefiore (CHAM) and Albert Einstein College of Medicine, describes the clinical characteristics and outcomes of children hospitalized with COVID-19, during the early days of the pandemic. (Source: Einstein News)
Source: Einstein News - May 20, 2020 Category: Universities & Medical Training Source Type: news

First-Of-Its-Kind Report Details How New York Children's Hospital Transformed to Provide Care to Adult COVID-19 Patients
NEW YORK (May 4, 2020)— Over the course of two weeks in March, COVID-19 cases at Montefiore grew from two to almost 700. As the health system looked to increase capacity, an inpatient pediatric unit at theChildren’s Hospital at Montefiore (CHAM), quickly became a 40-bed unit that would be home to adult patients. A new, first-of-its-kind report published in theJournal of Pediatrics describes the rapid transformation that took place. The report also shares valuable lessons learned and best practices for healthcare providers throughout the country, who may face a similar situation in the weeks ahead. (Source: Einstein News)
Source: Einstein News - May 5, 2020 Category: Universities & Medical Training Source Type: news

Cancer Patients Face High Mortality from COVID-19
May 1, 2020—(BRONX, NY)—People with cancer who develop COVID-19 are much more likely to die from the disease than those without cancer, according to physician-researchers atMontefiore Health System andAlbert Einstein College of Medicine. The study, published today in the online edition of Cancer Discovery, is the largest so far to assess outcomes for patients with cancer who have also been infected with COVID-19. (Source: Einstein News)
Source: Einstein News - May 1, 2020 Category: Universities & Medical Training Source Type: news

Trial of Highly Touted Drug Begins at Montefiore and Einstein
(BRONX, NY)—April 29, 2020—Researchers atMontefiore Health System andAlbert Einstein College of Medicine have begun testing the drughydroxychloroquine for the treatment of COVID-19, as part of a nationwide trial sponsored by the National Heart, Lung, and Blood Institute (NHLBI). (Source: Einstein News)
Source: Einstein News - April 29, 2020 Category: Universities & Medical Training Source Type: news

Clinical Trial Begins to See if Convalescent Plasma Can Treat COVID-19
April 29, 2020—(BRONX, NY)—Montefiore Health System,Albert Einstein College of Medicine and NYU Langone have launched a new clinical trial to study if convalescent plasma—taken from people who have recovered from COVID-19—is effective in treating the disease. (Source: Einstein News)
Source: Einstein News - April 29, 2020 Category: Universities & Medical Training Source Type: news

Einstein-Invented Compound Now Being Tested in COVID-19 Clinical Trial
April 28, 2020—(BRONX, NY)—A compound originally discovered byAlbert Einstein College of Medicine’sVern Schramm, Ph.D., is being evaluated by BioCryst Pharmaceuticals, Inc., in Brazil as a treatment for COVID-19 patients. The randomized, double-blind, placebo-controlled trial is funded by the National Institute of Allergy and Infectious Diseases. (Source: Einstein News)
Source: Einstein News - April 28, 2020 Category: Universities & Medical Training Source Type: news

Albert Einstein College of Medicine Holds Early Graduation to Help Confront COVID-19 Pandemic
April 17, 2020—(BRONX, NY)—Answering the call for additional medical workers to join the frontlines of the COVID-19 pandemic, today more than 100 medical students atAlbert Einstein College of Medicine graduated a month early. Many of these newly minted doctors will immediately join the staff of hospitals in New York City, contributing to the heroic efforts of medical teams who are treating patients fighting this devastating disease. (Source: Einstein News)
Source: Einstein News - April 17, 2020 Category: Universities & Medical Training Source Type: news

Slower Clearance of Coronavirus Infection May Explain Why Men Fare Worse Than Women
(BRONX, NY)—April 17, 2020—Researchers atMontefiore Health System andAlbert Einstein College of Medicine may have solved a mystery surrounding the novel coronavirus pandemic: Why men infected by the virus generally show more severe symptoms and are more likely than women to die from COVID-19. In collaboration with the Kasturba Hospital for Infectious Diseases in Mumbai, India, the scientists showed for the first time that men clear the virus from their bodies slower than women and found a possible explanation: a potential male-only“reservoir” for coronavirus. (Source: Einstein News)
Source: Einstein News - April 17, 2020 Category: Universities & Medical Training Source Type: news

Einstein Announces Early Graduation to Help Fight the COVID-19 Pandemic
Yesterday, Albert Einstein College of Medicine informed members of the class of 2020 that they may choose to graduate early, on Friday, April 17, if they have completed their curricular requirements. This voluntary opportunity was offered in order to provide support to hospitals as they continue to manage the surge of COVID-19 patients in New York City and beyond. Students also may choose to graduate on the original date of May 26. (Source: Einstein News)
Source: Einstein News - April 11, 2020 Category: Universities & Medical Training Source Type: news

Montefiore and Einstein Begin Clinical Trial for Severely Ill COVID-19 Patients
(BRONX, NY)—April 3, 2020—Montefiore Health System andAlbert Einstein College of Medicine has started treating very sick COVID-19 patients as part of a multicenter trial evaluating a potential therapy for the new disease. The double-blind, placebo-controlled trial is testing whether sarilumab, a drug already approved for treating rheumatoid arthritis, can halt the inflammation that can overwhelm the lungs of COVID-19 patients. A very similar drug yielded promising results in a recent study involving patients in China. (Source: Einstein News)
Source: Einstein News - April 3, 2020 Category: Universities & Medical Training Source Type: news

Clinical Trial for Severely Ill COVID-19 Patients Now Underway at Montefiore-Einstein
(BRONX, NY)—April 3, 2020—Montefiore Health System andAlbert Einstein College of Medicine has started treating very sick COVID-19 patients as part of a multicenter trial evaluating a potential therapy for the new disease. The double-blind, placebo-controlled trial is testing whether sarilumab, a drug already approved for treating rheumatoid arthritis, can halt the inflammation that can overwhelm the lungs of COVID-19 patients. A very similar drug yielded promising results in a recent study involving patients in China. (Source: Einstein News)
Source: Einstein News - April 3, 2020 Category: Universities & Medical Training Source Type: news

Trial for Potential Coronavirus Treatment is Underway at Montefiore and Einstein
April 3, 2020—(BRONX, NY)—Montefiore Health System andAlbert Einstein College of Medicine has joined a clinical trial to evaluate the experimental drug remdesivir to treat people who are hospitalized with severe COVID-19 infection. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is sponsoring the trial. This treatment has the potential to help people who have serious lung complications as a result of COVID-19. Recruitment for the trial began in March and is still underway. (Source: Einstein News)
Source: Einstein News - April 3, 2020 Category: Universities & Medical Training Source Type: news

Clement Tagoe, M.D., Ph.D., Named Chief of Rheumatology
March 23, 2020—(BRONX, NY)—Clement Tagoe, M.D., Ph.D., has been named chief of the Division of Rheumatology at Einstein and Montefiore, effective April 1. He replaces Chaim Putterman, M.D., who helped make the rheumatology division a national leader in its field during his 26 years here. (Source: Einstein News)
Source: Einstein News - March 23, 2020 Category: Universities & Medical Training Source Type: news

Einstein Students Learn Match Results Amid COVID-19 Crisis
March 20, 2020—(BRONX, NY)—Amid a sobering global pandemic with medical professionals performing heroic work around the world, fourth-year medical students ofAlbert Einstein College of Medicine, a part ofMontefiore, learned today by email where they will begin their residencies at hospitals across the nation. (Source: Einstein News)
Source: Einstein News - March 20, 2020 Category: Universities & Medical Training Source Type: news

Experimental Drug May Prevent Chemotherapy Drug from Damaging the Heart
March 3, 2020—(BRONX, NY)—The commonly used chemotherapy drug doxorubicin can damage heart muscle, in some cases leading to severe or lethal heart failure. A new study led byAlbert Einstein College of Medicine researchers and involving zebrafish and mice suggests that the experimental drug BAI1 can prevent doxorubicin from damaging the heart without lessening its anti-cancer properties. The study was published online in the journalNature Cancer. (Source: Einstein News)
Source: Einstein News - March 3, 2020 Category: Universities & Medical Training Source Type: news

Michelle Ng Gong, M.D., M.S., Named Chief of Division of Pulmonary Medicine
February 21, 2020—(BRONX, NY)—Michelle Ng Gong, M.D., M.S., an internationally renowned clinician and researcher, has been named chief of the division of pulmonary medicine atAlbert Einstein College of Medicine andMontefiore Health System. Dr. Gong is currently chief of the division of critical care medicine at Einstein and Montefiore, as well as leader of the unified Jay B. Langer Critical Care Network. (Source: Einstein News)
Source: Einstein News - February 21, 2020 Category: Universities & Medical Training Source Type: news

Susan Band Horwitz Wins Prestigious Cancer Research Award for Anti-Tumor Drug Discovery
February 14, 2020—(BRONX, NY)—Susan Band Horwtiz, Ph.D., distinguished professor of molecular pharmacology and the Rose C. Falkenstein Chair in Cancer Research at Albert Einstein College of Medicine, has been awarded the National Foundation for Cancer Research’s (NFCR) 2020 Szent-Györgyi Prize for Progress in Cancer Research. The honor recognizes her pioneering research establishing the mechanism of action of anti-tumor drugs, including Taxol, that are used to treat ovarian, breast, and lung cancers. (Source: Einstein News)
Source: Einstein News - February 14, 2020 Category: Universities & Medical Training Source Type: news

Montefiore and Albert Einstein College of Medicine Secure $5.9 Million NCI Grant to Improve Cancer Care for Minority and Underserved Communities
January 29, 2020—(BRONX, NY)—Montefiore, the University Hospital ofAlbert Einstein College of Medicine, has received a $5.9 million grant from the National Cancer Institute (NCI) to build on its success recruiting minority and underserved patients into cancer clinical trials and delivering the highest quality cancer care. This new grant, part of the NCI Community Oncology Research Program (NCORP), is a continuation of funding first awarded in 2014. (Source: Einstein News)
Source: Einstein News - January 29, 2020 Category: Universities & Medical Training Source Type: news

Reducing Blood Cancer Patients' Need for Transfusions
January 21, 2020—(BRONX, NY)—A clinical trial has found the drug luspatercept significantly reduced the need for blood transfusions in people with lower-risk myelodysplastic syndromes (MDS), a group of bone marrow disorders that leave people with many defective blood cells and too few normal ones. Approval by the Food and Drug Administration (FDA) would make luspatercept the first new drug available to MDS patients in 12 years.Results of the phase 3 clinical trial were published online January 9 in the New England Journal of Medicine (NEJM). (Source: Einstein News)
Source: Einstein News - January 22, 2020 Category: Universities & Medical Training Source Type: news

Einstein and Montefiore Receive Accreditation for Interprofessional Continuing Education
January 16, 2020—(BRONX, NY)—Albert Einstein College of Medicine andMontefiore Health System have received Joint Accreditation for Interprofessional Continuing Education, certifying their ability to provide interprofessional continuing education (IPCE) for members of the medical profession, including physicians, nurses, and pharmacists. Einstein and Montefiore join fewer than 25 combined medical schools and health systems nationally that have received IPCE accreditation. (Source: Einstein News)
Source: Einstein News - January 16, 2020 Category: Universities & Medical Training Source Type: news

Einstein ’s 2020 Stem Cell Symposium Spotlights RNA Biology and Gene Editing
January 13, 2020—(BRONX, NY)—On Friday, January 17, Albert Einstein College of Medicine will host its 4th Stem Cell Symposium. This year’s event will feature lectures from leading investigators in the fields of RNA biology and the use of gene editing in stem cell research. (Source: Einstein News)
Source: Einstein News - January 13, 2020 Category: Universities & Medical Training Source Type: news

Einstein and Montefiore Present Research and Clinical Advances at American Society of Hematology Annual Meeting
Researchers and clinicians fromAlbert Einstein College of Medicine andMontefiore Health System were well-represented at the 61st American Society of Hematology (ASH) Annual Meeting& Exposition in Florida, the world’s largest gathering of experts who treat and study blood diseases. Faculty members delivered 12 oral presentations and dozens of poster presentations at the conference, which attracted more than 30,000 participants and showcased the latest advances in hematology. (Source: Einstein News)
Source: Einstein News - December 23, 2019 Category: Universities & Medical Training Source Type: news

Einstein Receives $178 Million in NIH Funding in Fiscal Year 2019, Largest Annual Total in Institution's History
December 10, 2019—BRONX, NY— Researchers atAlbert Einstein College of Medicine secured $178 million from the National Institutes of Health in federal fiscal year 2019, marking the largest annual total in the institution’s history (excluding supplemental stimulus funding distributed as a part of the American Recovery and Reinvestment Act of 2009). Major grants included those to lead international consortiums to study Ebola and HIV, as well as those focusing on neuroscience, genetics, and improving health among minority groups. (Source: Einstein News)
Source: Einstein News - December 10, 2019 Category: Universities & Medical Training Source Type: news

Einstein Awarded $8 Million to Use Wearable Tech to Improve Detection of Leg Arterial Disease
November 21, 2019—(BRONX, NY)—Lower extremity arterial disease (LEAD) is a debilitating but under-recognized condition usually caused by fatty plaque buildup in arteries carrying blood from the heart to the legs. More commonly known as peripheral artery disease, this increasingly common condition affects more than 8 million Americans, including up to 20% of those over the age of 60, and over 200 million people worldwide. Left untreated, LEAD can result in disability, amputations, and death. (Source: Einstein News)
Source: Einstein News - November 21, 2019 Category: Universities & Medical Training Source Type: news

Two Einstein Researchers Honored During Kidney Week
November 20, 2019—(BRONX, NY)—ForMichal Melamed, M.D., mentoring means guiding people to do things they may not have thought they could do and helping them succeed at their highest level. During its annual Kidney Week meeting, the American Society of Nephrology (ASN) recognized Dr. Melamed, associate professor of medicine and of epidemiology& population health atAlbert Einstein College of Medicine, and a nephrologist atMontefiore Health System, for her mentoring achievements and presented her with its Distinguished Mentor Award. (Source: Einstein News)
Source: Einstein News - November 20, 2019 Category: Universities & Medical Training Source Type: news

Two Einstein Researchers Honored During Kidney Week
November 19, 2019—(BRONX, NY)—ForMichal Melamed, M.D., mentoring means guiding people to do things they may not have thought they could do and helping them succeed at their highest level. During its annual Kidney Week meeting, the American Society of Nephrology (ASN) recognized Dr. Melamed, associate professor of medicine and of epidemiology& population health atAlbert Einstein College of Medicine, and a nephrologist atMontefiore Health System, for her mentoring achievements and presented her with its Distinguished Mentor Award. (Source: Einstein News)
Source: Einstein News - November 20, 2019 Category: Universities & Medical Training Source Type: news

Montefiore Medicine Names Philip O. Ozuah, M.D., Ph.D., as CEO
NEW YORK (November 5, 2019)— Montefiore Medicine’s Board of Trustees announced today that Dr. Philip O. Ozuah has been named the next Chief Executive Officer of Montefiore Medicine, the umbrella organization for Montefiore Health System (MHS) and Albert Einstein College of Medicine. As CEO, Dr. Ozuah will lead Montefiore Medicine’s next phase of growth and evolution as a global healthcare leader, renowned for its leading medical school, groundbreaking research and technology, and highly specialized, coordinated care of diverse populations in the New York region, across the country and globally. Dr. Ozuah ...
Source: Einstein News - November 5, 2019 Category: Universities & Medical Training Source Type: news

Montefiore Medicine Names Philip O. Ozuah, MD, PhD, as CEO
NEW YORK (November 5, 2019)— Montefiore Medicine’s Board of Trustees announced today that Dr. Philip O. Ozuah has been named the next Chief Executive Officer of Montefiore Medicine, the umbrella organization for Montefiore Health System (MHS) and Albert Einstein College of Medicine. As CEO, Dr. Ozuah will lead Montefiore Medicine’s next phase of growth and evolution as a global healthcare leader, renowned for its leading medical school, groundbreaking research and technology, and highly specialized, coordinated care of diverse populations in the New York region, across the country and globally. Dr. Ozuah ...
Source: Einstein News - November 5, 2019 Category: Universities & Medical Training Source Type: news

Einstein Enrichment Program Receives 2019 Inspiring Programs in STEM Award
October 29, 2019—(BRONX, NY)—Albert Einstein College of Medicine’s pipeline program for middle and high school students has received a 2019 Inspiring Programs in STEM Award from INSIGHT Into Diversity magazine. (Source: Einstein News)
Source: Einstein News - October 29, 2019 Category: Universities & Medical Training Source Type: news

Einstein and CUNY School of Public Health Collaborate to Offer Medical Students M.D./M.P.H. Program
October 10, 2019—(BRONX, NY)—Albert Einstein College of Medicine and theCUNY Graduate School of Public Health and Health Policy (CUNY SPH) announced an agreement today to offer Einstein medical students an opportunity to complete a five-year program resulting in a Doctor of Medicine (M.D.) degree from Einstein and a Master’s Degree in Public Health (M.P.H.) degree from CUNY SPH. (Source: Einstein News)
Source: Einstein News - October 10, 2019 Category: Universities & Medical Training Source Type: news

9/11 World Trade Center Exposure Linked to Heart Disease Among NYC Firefighters
September 6, 2019—BRONX, NY—A new study of New York City firefighters has found that exposure to 9/11 World Trade Center (WTC) dust is associated with a significantly increased long-term risk of cardiovascular disease (CVD). The study, conducted by researchers atAlbert Einstein College of Medicine,Montefiore Health System, and theFire Department of the City of New York (FDNY), found that those who arrived first at the WTC site—when the air-borne dust was thickest—have a 44% increased risk of CVD compared to those who arrived later in the day. The study was published online today inJAMA Network Open....
Source: Einstein News - September 6, 2019 Category: Universities & Medical Training Source Type: news

On Becoming a Physician: New Einstein Students Receive White Coats and Stethoscopes
August 19, 2019—(BRONX, NY)—Members of Albert Einstein College of Medicine’s class of 2023 received monogrammed white coats and stethoscopes last week in a ceremony marked with pride and reminders of responsibility as they embark on their lifelong journey of medical education. (Source: Einstein News)
Source: Einstein News - August 19, 2019 Category: Universities & Medical Training Source Type: news

Novel Therapy for Acute Migraine Shows Promise in Phase 3 Clinical Trial
July 10, 2019—(BRONX, NY)—A drug belonging to a new generation of acute migraine headache treatments was found to eliminate pain and reduce bothersome symptoms for people with migraine in a large-scale trial reported in the July 11 issue of The New England Journal of Medicine. The drug, rimegepant, is awaiting U.S. Food and Drug Administration approval and may offer advantages over currently available migraine medications. The study was led by researchers atAlbert Einstein College of Medicine andMontefiore Health System. (Source: Einstein News)
Source: Einstein News - July 11, 2019 Category: Universities & Medical Training Source Type: news